Children aged 6 months to 12 years are the main spreaders of respiratory syncytial virus (RSV) infections within their ...
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing ...
GlobalData on MSN1d
Pfizer’s RSV vaccine wins expanded approval in EU, gaining edge over GSKAbrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...
Older adults and people with certain medical conditions are more likely to receive the respiratory syncytial virus (RSV) ...
Pfizer’s RSV vaccine Abrysvo receives European approval to help protect adults aged 18-59 against RSV lower respiratory tract disease: New York Wednesday, April 2, 2025, 09:00 H ...
The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...
Pfizer Inc. has announced that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO, the company’s bivalent respiratory syncytial ...
Australian medicines regulator, the Therapeutic Goods Administration (TGA), has granted approval for mRESVIA (mRNA-1345), an ...
An Australian-first study demonstrating the effectiveness of a new immunization against respiratory syncytial virus (RSV) for ...
The European Commission (EC) has issued a decision amending the marketing authorization for Abrysvo, US pharma giant Pfizer’s ...
The risk for new-onset or recurrent AF was not increased among older adult patients with preexisting conditions following RSV vaccination.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback